Centre for Vision Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
Macquarie University Hearing, Department of Linguistics, Macquarie University, Sydney, NSW, Australia.
Eye (Lond). 2023 Sep;37(13):2736-2743. doi: 10.1038/s41433-023-02407-0. Epub 2023 Jan 25.
BACKGROUND/OBJECTIVES: To examine the risk factors for poor vision-related and health-related quality of life (QoL) in patients with neovascular age-related macular degeneration (nAMD) who present for anti-vascular endothelial growth factor (anti-VEGF) therapy.
In a clinic-based cohort of 547 nAMD patients who presented for treatment, the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ25), Short-Form 36 (SF-36) and EuroQoL EQ-5D-5L questionnaires were administered to assess vision-related and health-related QoL. Of these, 83 participants were followed up one-year later to provide longitudinal data.
Individuals with mild or moderate visual impairment or blindness at baseline had significantly lower NEI-VFQ-25 scores at follow-up. The presence of ≥3 chronic diseases was associated with lower SF-36 mental component scores (MCS) (p = 0.04) and EQ-VAS scores (p = 0.05). Depressive symptoms were associated with significantly lower MCS (p < 0.0001) and EQ-VAS scores (p = 0.02). Individuals with versus without impaired basic activities of daily living (ADLs) exhibited NEI-VFQ-25 and EQ-VAS scores that were 10.96 (p = 0.03) and 0.13 (p = 0.02) points lower. Those with impaired instrumental ADLs scored 11.62 (p = 0.02), 13.13 (p < 0.0001) and 15.8 (p = 0.0012) points lower in the NEI-VFQ-25, SF-36 physical component score and EQ-5D-5L summary score, respectively.
The QoL of nAMD patients is affected by visual acuity as well as patients' medical history, mental health and functional status.
背景/目的：研究接受抗血管内皮生长因子（anti-VEGF）治疗的新生血管性年龄相关性黄斑变性（nAMD）患者中，与视力相关和健康相关的生活质量（QoL）较差的风险因素。
在一项基于诊所的 547 名 nAMD 患者队列中，对这些患者进行了国家眼科研究所视觉功能问卷-25（NEI-VFQ25）、短格式 36（SF-36）和 EuroQoL EQ-5D-5L 问卷调查，以评估与视力相关和健康相关的 QoL。其中，83 名参与者在一年后进行了随访，以提供纵向数据。
基线时存在轻度或中度视力障碍或失明的个体在随访时的 NEI-VFQ-25 评分显著较低。存在≥3 种慢性疾病与 SF-36 心理成分评分（MCS）较低（p=0.04）和 EQ-VAS 评分较低（p=0.05）相关。抑郁症状与 MCS（p<0.0001）和 EQ-VAS 评分显著降低相关（p=0.02）。存在基本日常生活活动（ADL）受损的个体的 NEI-VFQ-25 和 EQ-VAS 评分分别低 10.96（p=0.03）和 0.13（p=0.02）分。那些存在工具性 ADL 受损的个体的 NEI-VFQ-25、SF-36 生理成分评分和 EQ-5D-5L 综合评分分别低 11.62（p=0.02）、13.13（p<0.0001）和 15.8（p=0.0012）分。
nAMD 患者的 QoL 受视力以及患者的病史、心理健康和功能状态的影响。
